This cross-sectional study examines National Institutes of Health and pharmaceutical industry investments in recent drug approvals.

The drastic reduction in indirect costs is not a path to innovation or cost savings — it’s a threat to U.S.’s position as global leader in medical research.

This is a potentially devastating event — not just for the scientific community, but for all Americans.